Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Cisplatin + Gemcitabine + Sorafenib invasive bladder transitional cell carcinoma not applicable detail...
ERBB2 mutant Cisplatin + Gemcitabine + Sorafenib invasive bladder transitional cell carcinoma predicted - sensitive detail...
AKT1 mutant Cisplatin + Gemcitabine + Sorafenib invasive bladder transitional cell carcinoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01326871 Phase Ib/II ALT-801 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status
NCT03244384 Phase III Pembrolizumab Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting
NCT03534804 Phase II Pembrolizumab + Cabozantinib Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) Recruiting
NCT03558087 Phase II Cisplatin + Gemcitabine + Nivolumab Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing Recruiting
NCT03747419 Phase II Avelumab Avelumab and Radiation in Muscle-Invasive Bladder Cancer Recruiting
NCT03837821 Phase I Abemaciclib Window of Opportunity Trial of Abemaciclib for Bladder Cancer Recruiting